Akman B, Afsar B, Ataç F B, Ibis A, Arat Z, Sezer S, Ozdemir F N, Haberal M
Department of Nephrology, Baskent University Hospital, Ankara, Turkey.
Transplant Proc. 2006 Mar;38(2):413-5. doi: 10.1016/j.transproceed.2006.01.022.
Acute thrombotic complications remain a constant, proportionally increasing complication before and after renal transplantation. We sought to investigate predictors for a prothrombotic state that increased the risk of vascular access thrombosis, among chronic renal failure patients during the waiting period prior to cadaveric renal transplantation. Chronic renal failure patients awaiting cadaveric renal transplantation and followed between January 2002 and January 2005 were included in this study. The 109 subjects including, 61 females and 48 males of mean age: 47.4 +/- 12.9 years; There were 36 continuous ambulatory peritoneal dialysis and 73 hemodialysis patients. Serum albumin, prealbumin, CRP, d-dimer, fibrinogen, antithrombin III, anticardiolipin antibodies (immunoglobulins G and M), homocystein, vitamin B12, folic acid, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and total platelet count were measured in each patient. Factor V Leiden, prothrombin 20210, ACE and MTHFR gene mutations were studied in all patients. Vascular Access thrombosis was detected in 62 patients. During follow-up 31 of 109 patients died. Vascular access thrombosis occurred in 78 patients who survived and 31 who died. The patients who died showed a significantly higher rate of thrombosis than those who survived (P = .003, OR: 4.61, CI: 1.70 to 12.50). Among the above biochemical risk factors, multiple regression analysis and backward logistic analysis revealed that d-dimer was the strongest biochemical predictor of thrombosis (P = .013, RR: 17.8). Upon evaluation of genetic risk factors, only factor V Leiden mutation was related to vascular access thrombosis (P = .001). In conclusion, the presence of vascular access thrombosis is a risk factor for mortality during the waiting period for cadaveric renal transplantation. As patients with factor V Leiden mutation or high serum d-dimer levels are at high risk for vascular access thrombosis, we recommend close monitorizing of these patients and use of anticoagulant therapy during the waiting period prior to renal transplantation.
急性血栓形成并发症一直是肾移植前后持续存在且比例不断增加的并发症。我们试图在尸体肾移植等待期的慢性肾衰竭患者中,研究增加血管通路血栓形成风险的血栓前状态的预测因素。本研究纳入了2002年1月至2005年1月期间随访的等待尸体肾移植的慢性肾衰竭患者。109名受试者,包括61名女性和48名男性,平均年龄:47.4±12.9岁;其中36名持续非卧床腹膜透析患者和73名血液透析患者。检测了每位患者的血清白蛋白、前白蛋白、CRP、D-二聚体、纤维蛋白原、抗凝血酶III、抗心磷脂抗体(免疫球蛋白G和M)、同型半胱氨酸、维生素B12、叶酸、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和血小板总数。对所有患者研究了凝血因子V莱顿、凝血酶原20210、ACE和亚甲基四氢叶酸还原酶基因突变。62例患者检测到血管通路血栓形成。随访期间,109例患者中有31例死亡。血管通路血栓形成发生在78例存活患者和31例死亡患者中。死亡患者的血栓形成发生率显著高于存活患者(P = 0.003,OR:4.61,CI:1.70至12.50)。在上述生化危险因素中,多元回归分析和向后逻辑分析显示,D-二聚体是血栓形成最强的生化预测因素(P = 0.013,RR:17.8)。在评估遗传危险因素时,只有凝血因子V莱顿突变与血管通路血栓形成有关(P = 0.001)。总之,血管通路血栓形成的存在是尸体肾移植等待期死亡的危险因素。由于凝血因子V莱顿突变患者或血清D-二聚体水平高的患者血管通路血栓形成风险高,我们建议在肾移植等待期密切监测这些患者并使用抗凝治疗。